kabutan

Nano Holdings, Inc.(4571) Summary

4571
TSE Growth
Nano Holdings, Inc.
167
JPY
-2
(-1.18%)
Mar 16, 9:07 am JST
1.04
USD
Mar 15, 8:07 pm EDT
Result
PTS
outside of trading hours
167.1
Mar 16, 9:07 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.82
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 16, 2026
Opening Mar 16, 9:00 am
166 JPY 1.04 USD
Previous Close Mar 13
169 JPY 1.06 USD
High Mar 16, 9:00 am
167 JPY 1.04 USD
Low Mar 16, 9:01 am
165 JPY 1.03 USD
Volume
93,400
Trading Value
0.02B JPY 0.10M USD
VWAP
166.37 JPY 1.04 USD
Minimum Trading Value
16,700 JPY 104 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
54
Liquidity & Number of Trades
As of Mar 16, 2026
Liquidity
Slightly High
1-Year Average
490
1-Year High Oct 10, 2025
15,902
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 7,910,200
Feb 27, 2026 0 8,192,100
Feb 20, 2026 1,500 8,019,100 5346.07
Feb 13, 2026 0 6,309,900
Feb 6, 2026 0 6,313,500
Company Profile
NANO MRNA Co., Ltd. is a biotech venture specializing in mRNA therapeutics. The company is expanding its pipeline through collaborations and partnerships, with high expectations for treating intractable cancers.
Sector
Pharmaceuticals
NANO MRNA Co., Ltd. has been developing innovative pharmaceuticals, primarily focusing on anticancer drugs that encapsulate small molecules and other medicines within nanoparticles using micellar nanoparticle technology. In January 2023, the company shifted its business model to concentrate on mRNA therapeutics. mRNA therapeutics involve administering artificially manufactured mRNA to the body, enabling the expression of proteins encoded by the mRNA to prevent or treat diseases. The company is advancing multiple mRNA pipelines, including regenerative medicine for osteoarthritis of the knee, immune tolerance vaccines, and preventive vaccines for infectious diseases. NANO MRNA conducts research and development up to the preclinical trial stage and then licenses out to pharmaceutical companies. The company actively pursues joint research with academia, pharmaceutical, and non-pharmaceutical companies to expand its pipeline of new candidates. In addition to mRNA, NANO MRNA continues to develop brain tumor treatments and siRNA drugs targeting transcription factors. The company aims to establish a development system rivaling major pharmaceutical companies and create innovative medicines.